OricPharma logo
Publications
CD73 INHIBITOR PROGRAM: ORIC-533
ORIC publications
CD73 inhibition reverses immunosuppression and has potential as an immunomodulatory therapy in patients with multiple myeloma
Poster presented at: 2022 American Society of Hematology Annual Meeting, December 10-13, 2022. Poster #4472
ORIC-533, a Small Molecule CD73 Inhibitor with Best-in-Class Properties, Reverses Immunosuppression and Has Potential as an Immunomodulatory Therapy in Patients with Multiple Myeloma
Poster presented at: 2022 American Association for Cancer Research Annual Meeting, April 8-13, 2022. Abstract # 2074
Blocking Adenosine Production with ORIC-533, a CD73 Inhibitor with Best-In-Class Properties, Reverses Immunosuppression in High-AMP Environments
Poster presented at: 2021 American Association for Cancer Research Virtual Annual Meeting, April 10-15, 2021. Abstract # LB-163
CD73 inhibition with a novel orally bioavailable small molecule blocks adenosine production and rescues T-cell activation
Poster presented at: 2020 American Association for Cancer Research; June 22-24, 2020. Poster #1023
An orally bioavailable inhibitor of CD73 reverts intratumoral immunosuppression and promotes anti-tumor response
Poster presented at: 2020 American Association for Cancer Research; June 22-24, 2020. Poster #LB-115
Orally available small molecule CD73 inhibitor reverses immunosuppression through blocking of adenosine production
Presented at: 2020 American Association for Cancer Research; April 27, 2020. Abstract #1242, presentation 1037.
Intratumoral immunosuppression is reversed by blocking adenosine production with an oral inhibitor of CD73
Poster presented at: 2019 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; October 27, 2019; Boston, MA, USA. Abstract LB-A19.
EGFR/HER2 INHIBITOR PROGRAM: ORIC-114
ORIC publications
ORIC-114, an Orally Bioavailable, Irreversible Kinase Inhibitor, Has Superior Brain Penetration and Antitumor Activity in Subcutaneous and Intracranial NSCLC Models
Poster presented at: 2022 American Association for Cancer Research Annual Meeting, April 8-13, 2022. Abstract #3335
ORIC-114, an Orally Bioavailable, Irreversible Kinase Inhibitor, Has Superior Brain Penetrant Properties and Enhanced Potency in Preclinical Studies of HER2-Positive Breast Cancer
Poster presented at: AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, October 7-10, 2021. Poster # P234
ORIC-114, a Brain Penetrant, Orally Bioavailable, Irreversible Inhibitor Selectively Targets EGFR and HER2 Exon 20 Insertion Mutants and Regresses Intracranial NSCLC Xenograft Tumors
Poster presented at: 2021 American Association for Cancer Research Virtual Annual Meeting, April 10-15, 2021. Abstract #1466
PRC2 INHIBITOR PROGRAM: ORIC-944
ORIC publications
Biomarker strategy for a phase 1 study of ORIC-944, a potent and selective allosteric PRC2 inhibitor, in patients with metastatic prostate cancer
Poster presented at: 2023 American Association for Cancer Research Annual Meeting, April 14-19, 2023. Abstract #2791
ORIC-944, a Potent and Selective Allosteric PRC2 Inhibitor, Demonstrates Robust In Vivo Activity in Prostate Cancer Models
Poster presented at: 2021 American Association for Cancer Research Virtual Annual Meeting, April 10-15, 2021. Abstract #1131
PLK4 INHIBITOR PROGRAM
ORIC publications
Selective PLK4 Inhibitors Demonstrate Synthetic Lethality in TRIM37 Amplified Neuroblastoma and Breast Cancer Models While Less Selective Inhibitors Do Not
Poster presented at: 2023 American Association for Cancer Research Annual Meeting, April 14-19, 2023. Abstract #4998
Discovery of Novel, Highly Selective Inhibitors of PLK4 That Demonstrate In Vivo Regressions in TRIM37 High Xenografts
Poster presented at: 2022 American Association for Cancer Research Annual Meeting, April 8-13, 2022. Abstract #2633